

Welcome to the OncoSignal symposium

Hollywood room at 14:00

OncoSignal: mRNA tests to quantify oncogenic signaling pathway activity in cancer

Signaling pathway activity



Learn about OncoSignal:
During the symposium the OncoSignal technology will be explained and results will be presented of a retrospective study in ER positive breast cancer, illustrating the potential of molecular pathway activity scores to improve the choice of an effective therapy for the individual patient with cancer.



Drug response monitoring*



Stratification for clinical trials



Cancer research

Visit our booth #C2

www.philips.com/oncosignal

Ground breaking molecular phenotyping

interpretation of transcriptomic data in terms of possible actionable signal transduction pathway activities

Personalized cancer treatment requires knowledge on active tumor driving signal transduction pathways to select the optimal effective treatment. OncoSignal is the first test which translates transcriptomic data from cancer samples into quantifiable signal transduction pathway activities as an aid in patient specific therapy choice.

Based on mRNA analysis, OncoSignal enables simultaneous measurement of several tumor driving signal transduction pathway activities, and provides a quantitative activity score for each of these dynamic biomarkers to serve as an aid in therapy choice. OncoSignal tests can be performed on cell or tissue samples, either fresh frozen or formalin fixed paraffin embedded (FFPE), and can in principle be used for all types of cancer, including rare cancers.

qPCR-based OncoSignal tests can be performed in a service lab setting, however the test will also become available for “in-house” testing using standard qPCR equipment to enable same-day sample analysis results. In addition, OncoSignal pathway analysis can also be performed on Affymetrix expression microarray and RNA sequencing data.

Literature

- *'Estrogen Receptor pathway activity score to predict clinical response or resistance to neo-adjuvant endocrine therapy in primary breast cancer'*; Molecular Cancer Therapeutics, 2019
- *'Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients'*; International Journal of Cancer, 2019
- *'Quantitative Measurement of Functional Activity of the PI3K Signaling Pathway in Cancer'*; Cancers, 2019
- *'Enabling precision medicine by unravelling disease pathophysiology: quantifying signal transduction pathway activity across cell and tissue types'*; Nature Scientific Reports, 2019
- *'Assessment of Functional Phosphatidylinositol 3-Kinase Pathway Activity in Cancer Tissue Using Forkhead Box-O Target Gene Expression in a Knowledge-Based Computational Model'*; The American Journal of Pathology, 2018
- *'Selection of Personalized Patient Therapy through the Use of Knowledge-Based Computational Models That Identify Tumor-Driving Signal Transduction Pathways'*; Cancer Research, 2014
- *'Knowledge-based computational models'*; Oncotarget, 2014

For more information, please contact the OncoSignal team at oncosignal@philips.com

For Research Use Only – not for use in diagnostic procedures.

© 2020 Koninklijke Philips N.V. All rights reserved. Specifications are subject to change without notice. Trademarks are the property of Koninklijke Philips N.V.(Royal Philips) or their respective owners.

www.philips.com/oncosignal

